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 Introduction 
 Neovascular glaucoma (NVG) is a severe condition re-
sulting from ischemia induced by various ocular diseas-
es, such as proliferative diabetic retinopathy, retinal vein 
occlusion, radiation retinopathy, and chronic uveitis  [1, 
2] . In NVG, neovascularization of the iris and anterior 
chamber angle – mediated by vascular endothelial growth 
factor (VEGF) – leads to elevated intraocular pressure 
(IOP)  [3–6] . Production of VEGF in NVG eyes is trig-
gered by hypoxia of the retina  [2, 5] . In order to lower the 
raised IOP in patients with NVG, both surgical and med-
ical treatment strategies have been established, such as 
cyclophotocoagulation or the application of IOP-lower-
ing drops  [1] . Retinal ischemia and the resulting increase 
in intravitreal VEGF levels, which represent the leading 
pathomechanism in the development of NVG, are re-
duced by performing panretinal laser photocoagulation 
(PRP) or cryocoagulation.
 However, at least in the short term, photocoagulation 
alone may not be enough to prevent the progression of 
NVG – especially in cases with severe and rapid progres-
sion of NVG  [1] . Despite several treatment modalities be-
ing available, visual prognosis is poor and the risk of re-
quiring enucleation in cases of painful amaurosis is high.
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 Abstract 
 Purpose: To assess the duration of the effect of intracameral 
bevacizumab in patients presenting with rubeosis iridis and 
neovascular glaucoma (NVG).  Methods: Retrospective anal-
ysis of 24 consecutive eyes of 24 patients with decompen-
sated NVG ( 1 21 mm Hg) treated with a single intracameral 
injection of bevacizumab over a minimum follow-up of 6 
months. The endpoint of the study was the need for retreat-
ment due to recurrence of raised intraocular pressure (IOP). 
Secondary outcome was the course of visual acuity (VA) and 
IOP over 6 months.  Results: A Kaplan-Meier calculation re-
vealed a mean duration of the treatment effect of 23  8 4.4 
days. Compared to mean IOP before treatment (26.3 mm 
Hg), decreases to 17.5 mm Hg at 1 week after treatment (p  ! 
0.002) and to 17.1 mm Hg (p  ! 0.005) at 6 months following 
a single injection were seen. At 6 months, additional treat-
ment was performed in 87.5% (n = 21) of eyes. VA remained 
stable or improved in 75% (n = 18) of all cases.  Conclusion: 
The IOP-lowering effect of intracameral bevacizumab can be 
seen 1 week after the injection, but is limited to a period of 
approximately 3 weeks. However, the fast and effective re-
sponse to intracameral bevacizumab injection opens a time 
window for additional treatments, which are often neces-
sary.  Copyright © 2011 S. Karger AG, Basel 
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 Several studies have shown that the monoclonal anti-
body bevacizumab can be applied intravitreally as well as 
intracamerally to reduce neovascularization of the iris 
and thus lower IOP  [7–11] , but recurrences of elevated 
IOP are frequent  [11] . Therefore, intraocular bevacizu-
mab may be considered as a temporary treatment that 
reduces IOP and thereby opens the window for addition-
al treatments which could not be performed initially  [12] .
 Although treatment effects have been described by 
several authors, little is known about the duration of the 
effect following a single injection of bevacizumab and 
whether additional treatments should be applied. While 
such data has been recently published for the intravitreal 
application  [11, 13] , no data is available for a single in-
tracameral application of bevacizumab. The aim of this 
retrospective study was to observe the sustainability of 
the effect of a single intracameral injection of bevacizum-
ab over time in patients presenting with decompensated 
NVG.
 Patients and Methods 
 The authors retrospectively reviewed 32 patient files and in-
cluded 24 consecutive eyes of 24 patients who received intracam-
eral bevacizumab (Avastin  ; Gentech, Inc. South San Francisco, 
Calif., USA) between September 2006 and December 2007 for the 
treatment of decompensated NVG over a minimum follow-up of 
6 months. NVG was defined as IOP  1 21 mm Hg, with the pres-
ence of rubeotic vessels in the anterior chamber angle or corneal 
edema and obvious rubeosis iridis in cases where the anterior 
chamber angle was not accessible. The primary ocular diseases 
that led to the development of NVG are listed in  table 1 . An ad-
ditional treatment at any time point was defined as the endpoint 
of this retrospective analysis.
 All eyes had follow-up examinations at 1 week, 1 month, and 
6 months after intracameral bevacizumab application. The re-
cords were reviewed for best corrected visual acuity (BCVA; mea-
sured by ETDRS charts if available), IOP (measured by Gold-
mann applanation tonometry), and the number of glaucoma 
medications. All patients included had previously been treated by 
PRP. In some cases, this treatment could not be continued due to 
corneal edema. Intracameral as opposed to intravitreal injection 
was preferred, as we assumed that higher drug concentrations 
would be achieved in the anterior segment.
 Informed consent was obtained from each patient prior to the 
operation. All patients were informed about the ‘off-label’ use of 
bevacizumab and the experimental approach. This study was ap-
proved by the local institutional review board.
 A 50-  l aliquot of bevacizumab (25 mg/ml) was prepared for 
each patient. After aseptic preparation (10% povidone-iodine so-
lution) and topical anesthetic eye drops (propacain 2%), 0.05 ml 
bevacizumab solution was injected using a 27-gauge needle at the 
limbus in the temporal quadrant. Standard postoperative treat-
ment included topical antibiotic eye drops (Ofloxacin, Floxal  , 
Alcon, Hünenburg, Switzerland) for 4 days. IOP and VA were 
monitored in all cases at 1 week and 1 month postoperatively, and 
at the clinical endpoint. Thereafter, the patients were reviewed at 
differing time spans. A rise in IOP was interpreted as a recurrence 
of NVG requiring further treatment.
 We defined the need for additional treatment, such as cryo-
coagulation or completion of PRP as well as glaucoma proce-
dures (e.g. cyclophotocoagulation), as the clinical endpoint of 
the analysis. The time interval since the intracameral drug ap-
plication and the nature of the surgical intervention were docu-
mented.
 Data were collected using a Microsoft Excel spreadsheet. The 
statistical software BIAS (Ackermann, Frankfurt, Germany) was 
used to compare means of continuous variables using Student’s t 
test. Non-parametric values were compared with the paired 
Mann-Whitney-White test. Values of p  ^  0.05 were considered 
statistically significant. For statistical analysis, VA was trans-
formed to LogMAR VA according to Colenbrander, as described 
by Duane  [14] . For graphical analysis, SPSS was used (SPSS Inc. 
Chicago, Ill., USA).
 Results 
 Of the 24 patients, 5 were female and 19 were male. 
The median age was 74 years (range 31–88 years).
 All eyes had been treated previously with PRP, and 12 
eyes had undergone photocoagulation (n = 8) or cryoco-
agulation (n = 4) of the ciliary body. In 16 eyes, comple-
tion of PRP was prevented by corneal edema.
 Anterior chamber injection was performed without 
complication in all cases.
 Development of Rubeotic Vessels 
 Before intracameral drug application, the anterior 
chamber could be evaluated in 8 patients. All of these pa-
tients showed evident rubeotic vessels in the anterior 
chamber angle of more than 270° (6 patients with evident 
360-degree angle involvement).
 Iris neovascularizations completely resolved clinically 
in 22 eyes (92%) 1 week postoperatively; in 2 eyes (8%) 
marked neovascularization in the anterior chamber an-
gle was still present.
Table 1. P rimary ocular diseases that led to NVG in our sample
Eyes (n = 24) %
Venous occlusion 14 58
Diabetic retinopathy 4 17
Radiation retinopathy 3 12.5
Severe bulb trauma 3 12.5
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 During follow-up, a recurrence of rubeotic vessels of 
the iris occurred in all eyes (100%) at different intervals. 
The median interval to recurrence of iris neovasculariza-
tion was 18  8 57 days (range 8–160 days).
 Development of IOP 
 The mean IOP before intracameral injection of beva-
cizumab was 26.3  8 6.6 mm Hg (range 21–44 mm Hg), 
despite topical and systemic IOP-lowering medication. 
Over all patients, a decrease in IOP to 17.5  8 5.3 mm Hg 
(p  ! 0.002) was noted at 1 week after treatment, and to 
17.1  8 5.3 mm Hg (p  ! 0.005) after 6 months ( fig. 1 ). A 
lowered IOP was seen in 70% of the treated eyes and al-
lowed for the reduction/stoppage of oral glaucoma treat-
ment. In these eyes, an average baseline IOP of 31.13  8 
8.3 mm Hg and a decrease to 16.0  8 5.2 mm Hg after 1 
week were noted. In 30% of treated eyes, IOP remained 
unchanged.
 Along with the decrease in IOP after treatment, the 
percentage of patients requiring oral glaucoma medica-
tion decreased from 33% (n = 8) before treatment to 21% 
(n = 5) at 1 week, and further to 13% (n = 3) at time of re-
treatment (p  ^  0.001, exact Fisher test, crosstab).
 However, the number of topical medications was not 
affected during follow-up (preoperatively: median = 3, 
mean = 2.8; at last follow-up: median = 3, mean = 2.8).
 None of the eyes required enucleation due to uncon-
trollably painful glaucoma.
 Need for Retreatment after Intracameral 
Bevacizumab 
 At 1 week after treatment with intracameral bevaci-
zumab, further treatment due to persistently increased 
IOP was performed in 1 eye (4.2%). At 1 month, addi-
tional treatment was performed in 62.5% (n = 15) of
all cases. This number increased to 87.5% (n = 21) at 6 
months ( fig. 2 ). In the remaining cases (n = 3), IOP could 
be controlled by topical treatment and did not show a re-
currence of NVG ( fig. 2 ).
 The median time interval to additional treatment due 
to increased IOP was 26  8 31 days (range 2–150 days,). 
A Kaplan-Meier calculation of the survival time revealed 
an estimated median of 30  8 6.4 days (estimated mean: 
49.2  8 11.3 days).
 The most frequent additional treatment consisted of 
PRP, which was carried out in 12 eyes (50%). Of note, PRP 
could not be performed in any of these eyes prior to the 
intracameral bevacizumab application due to marked 
IOP-induced corneal edema, which significantly re-
gressed following the IOP-lowering effect of intracam-
eral bevacizumab. Cryocoagulation of the ciliary body 








































 Fig. 1. Median IOPs showing a significant reduction over time
(p  ! 0.005, Student’s t test). Kaplan-Meier calculation of the sur-
vival time revealed an estimated median of 30  8 6.4 days. 
 Fig. 2. Proportion of eyes undergoing additional treatment after 
intracameral bevacizumab. By 6 months, almost all eyes had un-
dergone additional treatment such as completion of PRP or pho-
to- or cryocoagulation of the ciliary body. 
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went pars plana vitrectomy (8%). Reasons for the pars pla-
na vitrectomies were a tractive retinal detachment in a 
patient with proliferative diabetic retinopathy 137 days 
after intracameral bevacizumab and a persistent vitreous 
hemorrhage in a patient with central retinal vein occlu-
sion 21 days after intracameral bevacizumab (both cases 
combined with endolaser photocoagulation). A retreat-
ment with intracameral bevacizumab was applied in 4 
eyes (16%). In 3 of the 4 eyes, the intracameral reinjection 
of bevacizumab was combined with cyclophotocoagula-
tion.
 Development of VA 
 Preoperatively, BCVA (logMAR) was +0.2 in 1 eye, be-
tween +1.3 and +0.7 in 3 eyes, and counting fingers in the 
remaining 20 eyes. Overall, 73% (18 eyes) revealed no 
change in VA during follow-up. In 5 eyes, a decreased VA 
at the end of follow-up was noted. Three eyes showed an 
improved VA compared to baseline at 1 week after treat-
ment, with 1 eye maintaining an improved BCVA until 
the end of follow-up at 6 months.
 Mean BCVA remained unchanged during the course 
of the study and was 1.9  8 1.1 logMAR before intracam-
eral bevacizumab, 1 week later (1.9  8 1.0 logMAR), and 
at 6 months (1.9  8 1.0 logMAR).
 Discussion 
 NVG is not only a sight-threatening but also a painful 
condition that may warrant enucleation of the eye. NVG 
may be the result of different retinal diseases, such as pro-
liferative diabetic retinopathy or retinal vein occlusion. 
As shown by the Diabetic Retinopathy Study  [15] and 
others  [16–18] , panretinal photocoagulation represents 
an effective treatment option in NVG by reducing retinal 
ischemia and consequently lowering intravitreal VEGF 
levels. However, according to clinical experience, it may 
take weeks until the IOP-lowering effect of such laser 
treatments can be measured. Additionally, retinal photo-
coagulation is sometimes rendered impossible due to cor-
neal edema resulting from elevated IOP.
 We hypothesized that potential benefits from in-
tracameral injection of anti-VEGF drugs (such as bevaci-
zumab) may be derived from the far earlier treatment  [7, 
8, 19] and the fact that it can be performed irrespective of 
the presence of media opacities. In addition, as advanced 
stages of NVG are often refractory to PRP alone, we as-
sumed that the application of an additional treatment 
modality may positively influence these severe cases, as 
it has been demonstrated by Ehlers et al.  [20] that a com-
bination of PRP with intravitreal bevacizumab increased 
the speed of regression of neovascularization when com-
pared to PRP alone.
 Bevacizumab is a full-length humanized antibody that 
binds all isoforms of VEGF. Recent case reports have 
demonstrated the use of off-label intravitreal bevacizu-
mab injections to treat NVG  [7–11] . These reports includ-
ed relatively large numbers of cases, and showed short- 
and mid-term efficacy and safety to reduce rubeosis iridis 
and NVG  [7–11] . However, as seen in clinical practice, 
there is a recurrence of increased IOP in many bevaci-
zumab-treated eyes and additional treatments may be-
come necessary. In contrast, the results of Wakabayashi 
et al.  [11] and Jonas et al.  [13] imply that additional treat-
ment may not be necessary in all eyes treated with intra-
vitreal bevacizumab. A treatment effect of an intravitreal 
injection lasting up to an average of 58 days in NVG with 
open anterior chamber angle has been reported  [11] . In 
contrast to these reports on intravitreal bevacizumab in-
jections, few data are available on the onset and efficacy 
of a single intracameral bevacizumab injection and on 
the rate of recurrences in terms of IOP increase following 
this treatment.
 Our data show that intracameral bevacizumab is fol-
lowed by a rapid decrease in IOP in the majority of cases. 
In addition, we were able to demonstrate that there is a 
recurrence of NVG in the majority of eyes over time, and 
that the time point of recurrence is variable as indicated 
by the large standard deviation. The earliest recurrence 
of increased IOP was noted as early as 8 days after in-
tracameral bevacizumab application. The earliest addi-
tional treatment was performed 2 days after intracam-
eral bevacizumab application. As shown by the Kaplan-
Meier analysis, a recurrence is found after a period of 4 
weeks.
 However, this obviously shorter effect (as compared to 
intravitreal injection) may be derived from a shorter half-
life: little is known about the half-life duration of in-
tracameral bevacizumab. In general, one may assume 
that intracamerally applied drugs have a shorter half-life 
than intravitreally applied drugs, as described for other 
drugs such as voriconazole  [21, 22] . The half-life of intra-
vitreal bevacizumab was calculated to be 4.32 days in an 
animal model and 9.8 days in humans  [23, 24] .
 Interestingly, at the 6-month follow-up, retreatment 
was necessary in the majority of eyes. This is in accor-
dance with recent data published by Jonas et al.  [13] . Our 
results indicate that retreatment – if it becomes neces-
sary – is performed within 3 weeks. However the wide 
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range in time until retreatment (of up to 150 days) indi-
cates that all eyes previously treated with intracameral 
bevacizumab should be followed closely in order to iden-
tify those patients where a retreatment is not necessary.
 As described before  [7] , the efficacy of a single in-
tracameral injection was impressive: a single application 
of the drug caused dramatic reduction in the biomicro-
scopically visible rubeotic vessels in 92% of the cases. As 
in previous studies on intravitreal bevacizumab, no ad-
verse events related to intracameral injection were noted.
 We failed to identify prognostic factors concerning the 
recurrence of NVG. Wakabayashi et al.  [11] reported that 
an IOP-lowering effect of intravitreal bevacizumab injec-
tions depends on the status of the anterior chamber angle, 
with a decrease in IOP seen only in cases with open ante-
rior chamber angle and no effect seen in eyes with closed 
angle. In our analysis, the angle could only be assessed in 
a limited number of cases due to corneal edema. There-
fore, we cannot comment on this prognostic factor in our 
study. However, the fact that at 6 months the majority of 
patients had undergone additional surgeries (including 
completion of PRP) may allow us to conclude that the 
eyes included in our study represented end-stage NVG 
with – at least to some extent – closed angles.
 In our study, we were able to stabilize VA in the major-
ity of patients and none of the patients underwent enucle-
ation during follow-up. Nevertheless, in 20% (5 eyes) vi-
sual function further deteriorated, which may be related 
to glaucoma damage or progression of the concomitant 
retinopathy.
 We are aware of the limitations of our study, including 
its retrospective design and limited follow-up, as well as 
a heterogenous group of patients with respect to the un-
derlying diseases. Therefore, it seems difficult to compare 
the efficacy of an intracameral bevacizumab injection as 
performed in our patients to studies in which the drug 
was applied intravitreally  [11] . A prospective comparative 
study addressing this point may be useful to further elu-
cidate this issue.
 The cases presented herein demonstrate the potential 
of an intracameral bevacizumab injection to lower IOP in 
NVG patients, reduce the need for IOP-lowering drugs, 
and achieve better conditions for additional treatments 
such as PRP (as all patients who underwent completion 
of PRP could not have done this before the intracameral 
bevacizumab injection due to corneal edema). We have 
learned from our investigation that such treatments 
mostly become necessary at approximately 20 days after 
intracameral bevacizumab injection. Regular measure-
ments of IOP following the intracameral injection appear 
mandatory in order to identify those few patients in 
whom IOP could be stabilized by a single intracameral 
injection and those who require earlier additional treat-
ments than indicated above.
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